<DOC>
	<DOCNO>NCT00354601</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel capecitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving docetaxel together carboplatin may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel together capecitabine work treat patient recurrent persistent ovarian epithelial cancer , fallopian tube cancer , peritoneal cavity cancer .</brief_summary>
	<brief_title>Docetaxel Capecitabine Treating Patients With Recurrent Persistent Ovarian Epithelial Cancer , Fallopian Tube Cancer , Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient recurrent persistent ovarian epithelial cancer , fallopian tube cancer , peritoneal cavity cancer treat docetaxel capecitabine . Secondary - Determine time progression patient treat regimen . - Determine toxicity regimen patient . - Determine quality life treatment patient . OUTLINE : Patients receive docetaxel IV 30 minute day 1 , 8 , 15 oral capecitabine twice daily day 1-21 . Treatment repeat every 28 day ≥ 6 course absence disease progression unacceptable toxicity . Quality life assess baseline , day 1 course , completion study treatment . After completion study treatment , patient follow every 2-3 month .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Ovarian epithelial adenocarcinoma Fallopian tube cancer Peritoneal cavity cancer Recurrent persistent disease 2 prior treatment regimen ( 1 regimen primary disease and/or 1 regimen recurrent disease ) Platinumresistant disease , define 1 following : Treatmentfree interval &lt; 6 month platinumbased therapy Disease progression platinumbased therapy Measurable disease physical exam , chest xray , CT scan , MRI No brain metastasis PATIENT CHARACTERISTICS : Gynecologic Oncology Group performance status 02 Life expectancy &gt; 6 month Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 8 g/dL Creatinine clearance ≥ 50 mL/min Bilirubin normal AST ALT alkaline phosphatase ( AP ) meet 1 follow criterion : AST ALT ≤ 5 time upper limit normal ( ULN ) AND AP normal AST ALT ≤ 1.5 time ULN AND AP ≤ 2.5 time ULN AST ALT normal AND AP ≤ 5 time ULN No peripheral neuropathy &gt; grade 2 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month completion study treatment No concurrent malignancy except curatively treat nonmelanoma skin cancer No prior invasive malignancy &lt; 5 year curative therapy No serious uncontrolled medical psychiatric illness would preclude study participation limit survival &lt; 6 month No history severe hypersensitivity reaction drug formulate polysorbate 80 fluoropyrimidine therapy fluorouracil No inability tolerate oral medication due bowel obstruction , lack physical integrity upper gastrointestinal tract , inability swallow , malabsorption syndrome No serious concurrent infection No clinically significant cardiac disease well control medication , include follow : Congestive heart failure Symptomatic coronary artery disease Symptomatic cardiac arrhythmia Myocardial infarction within past 12 month PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior docetaxel capecitabine fluoropyrimidine therapy Recovered prior therapy At least 2 week since prior major surgery At least 4 week since prior chemotherapy , hormone therapy , radiotherapy No concurrent chemotherapeutic agent , biological therapy , radiotherapy , investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
</DOC>